Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660959 · ClinicalTrials.gov registry record · Phase 3
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia
A Phase 3 study, sponsored by CardioKine.
- Completed
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
NCT00660959 is a Phase 3 study that has completed, run by CardioKine. The registered enrollment target is 106 participants.
The verdict
NCT00660959, a Phase 3 study, has completed, sponsored by CardioKine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
Study Summary
The present study is designed to confirm and extend the observation from previous studies that lixivaptan therapy corrects hyponatremia, in euvolemic subject, including subjects with SIADH.
Interventions
- DRUG placebo
- DRUG lixivaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660959
The ClinicalTrials.gov registry entry for NCT00660959 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CardioKine, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00660959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00660959 about?
NCT00660959 is a clinical study titled "Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia". The present study is designed to confirm and extend the observation from previous studies that lixivaptan therapy corrects hyponatremia, in euvolemic subject, including subjects with SIADH.
What is the current status of trial NCT00660959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2008-04.
What interventions are being tested in trial NCT00660959?
The interventions under investigation include: placebo (DRUG), lixivaptan (DRUG).
Who is sponsoring clinical trial NCT00660959?
This trial is sponsored by CardioKine, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.